Product Description
NKTT120 is an anti-iNKT cell monoclonal antibody that has the potential to rapidly and specifically deplete iNKT cells and, potentially, prevent vaso-occlusion. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28152086/)
Mechanisms of Action: NKT Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NKT
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Anemia, Sickle Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01783691 |
120-SCD1 | P1 |
Completed |
Anemia, Sickle Cell |
2015-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|